ESR1 and breast cancer: Both MCF7 DLL1 knockdowns (KD1 and KD2) exhibited reduced primary tumor growth in NSG mice (Fig. 2b, c) compared to control cells (that received an empty shRNA vector), corroborating observations in human patients with ER+ breast cancer (Fig. 1).